Abstract: A method for characterizing cancer organoid response to an immune cell based therapy, includes providing a panel of different combinations of cancer organoid cells and immune cells to culturing wells and culturing the different combination under conditions that support organoid growth. Brightfield and corresponding fluorescence images of the culturing wells are captured and provided to one or more trained machine learning algorithms that identify and distinguish cancer organoid cells from immune cells and characterize cancer organoid morphology changes caused by an immune cell based therapies, from which an analytical report including a characterization of cancer organoid cell death caused by the immune cell based therapy is provided.

Abstract: Disclosed herein are systems, methods, and compositions for treating a subject diagnosed with, or suffering from cancer. In some embodiments, the method comprises determining whether a tumor sample from the subject includes a cytotoxic gene signature, and treating the subject based on the determination. In some embodiments, the subject has or is suspected of having a loss of heterozygosity in human leukocyte antigen (HLA) class I genes. In some embodiments, the therapy comprises one or more checkpoint inhibitors. In some embodiments, the cancer is colorectal, uterine, stomach, lung, skin, head or neck, or non-small cell lung carcinoma.